Glucose Homeostasis in Pseudohypoparathyroidism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-19

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.

NCT03728959

Hypoparathyroidism

COMPLETED NA

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

NCT00708175

Bone Metabolism

COMPLETED PHASE4

Glucocorticoids Promote Osteoclast Survival

NCT00572299

Osteoporosis

TERMINATED

One Week Comparison Study of PTH and PTHrP Infusions

NCT01333267

Osteoporosis Hypercalcemia of Malignancy Hyperparathyroidism +1 more

WITHDRAWN PHASE1

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926

Type 2 Diabetes Mellitus Bone Remodeling

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pseudohypoparathyroidism type 1A (PHP1A) is a rare, genetic disorder caused by impaired stimulatory G-protein signaling due to heterozygous mutations in the gene, GNAS. The most severe form of the disease, PHP1A occurs when a GNAS mutation is inherited on the preferentially expressed maternal allele. A less severe form of the disease, pseudopseudohypoparathyroidism (PPHP), occurs when a GNAS mutation is inherited on the paternal allele. Clinically, PHP1A is characterized by multi-hormone resistance, cognitive impairment and early-onset obesity while PPHP has a mild phenotype without multi-hormone resistance. It is increasingly recognized that PHP1A is associated with an increased risk of type 2 diabetes but the mechanism is unknown. Glucose homeostasis and diabetes risk has not been studied in PPHP. As part of the parent K23 award, we investigated glucose tolerance in children with PHP1A. In contrast to the adult literature, we found that children with PHP1A had greater insulin sensitivity than matched controls. When challenged with an oral glucose load, however, children with PHP1A had persistent hyperglycemia and 25% met criteria for impaired glucose tolerance. The goal of this proposal is to quantify β-cell function in PHP1A. It is plausible that these individuals have a) impaired β-cell function, b) differences in insulin sensitivity, and c) impaired incretin function. Thus, in this pilot study we will definitively assess one of these, β-cell function, using the frequently sampled intravenous glucose tolerance test in patients with PHP1A and PPHP (aim 1). We will also assess oral glucose tolerance over time by bringing back children and young adults with PHP1A from our original cohort for repeat glucose tolerance testing (aim 2). The ultimate goal is to rigorously define glucose homeostasis defects in PHP1A in order to design and conduct an intervention study for glucose intolerance and type 2 diabetes in PHP1A.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism Pseudohypoparathyroidism Type Ia Albright Hereditary Osteodystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pseudphypoparathyroidism type 1A (PHP1A)

Case

No interventions assigned to this group

Pseudopseudohypoparathyroidism (PPHP)

Case

No interventions assigned to this group

Controls

Matched control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of PHP1A/PPHP
2. Age between 6 and 50 years old

Controls will be matched based on:

1. Gender
2. Race
3. Age (±2 years if \<25 years old or ±5 years if ≥25 years old)
4. BMI (±2 kg/m2)
5. Diabetes status

Exclusion Criteria

1. Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
2. Type 1 diabetes
3. Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c \>9%at their most recent clinic visit
4. Pregnant or lactating women

Minimum Eligible Age

6 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No